An Economic Comparison of Healthcare Resource Use and Cost of ddMVAC and Cisplatin vs Gemcitabine and Cisplatin as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

Read it now on PracticeUpdate.com

Read the full article here

Source: PracticeUpdate
Categories: Latest Headlines, Urology
Tags: ,
Tweets with this article
Guru Sonpavde, MD
Neoadjuvant #chemo for muscle-invasive #bladdercancer-Adjusting for Performance Status & age indicated lower costs with GC vs. ddMVAC-single institution study (n=137) @DanaFarber_GU https://t.co/NLtneYrbz4 @practiceupdate

Related Articles